BEIJING Two COVID-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in…
By Reuters - 03 February 2021 The Sinopharm vaccine is approved in China for general public use and is also used in other countries, including the United Arab Emirates. Image: REUTERS/ TINGSHU WANG
Two Covid-19 vaccines from Chinese companies, including Sinopharm, triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small sample lab study showed.
Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.
Twelve serum samples taken from recipients of two vaccines developed by a subsidiary of China National Pharmaceutical Group (Sinopharm) and a unit of Chongqing Zhifei Biological Products retained neutralising activity against the South African variant, their researchers said in a paper.
Sinopharm s COVID-19 vaccine remained active against South Africa variant, effect reduced: lab study
FILE PHOTO: A signage of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang/File Photo reuters tickers
This content was published on February 3, 2021 - 05:03
February 3, 2021 - 05:03
BEIJING (Reuters) - Two COVID-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small-sample lab study released on Tuesday showed.
Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.
BEIJING (REUTERS) - Two Covid-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small-sample lab study released on Tuesday (Feb 2) showed.
Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.
Twelve serum samples each taken from recipients of two vaccines developed by a subsidiary of China National Pharmaceutical Group (Sinopharm) and a unit of Chongqing Zhifei Biological Products retained neutralising activity against the South African variant, their researchers said in a paper.
February 3, 2021 | 6:12 pm Font Size
AAA
BEIJING Two COVID-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small-sample lab study released on Tuesday showed.
Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.
Twelve serum samples each taken from recipients of two vaccines developed by a subsidiary of China National Pharmaceutical Group (Sinopharm) and a unit of Chongqing Zhifei Biological Products retained neutralizing activity against the South African variant, their researchers said in a paper.